Immuron Ltd — Capital/Financing Update 2012

Jun 17, 2012

==> picture [193 x 41] intentionally omitted <==

ABN: 80 063 114 045 Level 1, 39 Leveson Street North Melbourne, Vic 3051 Tel: +61 3 8637 1107 Fax: +61 3 9328 1675 www.immuron.com

Share Purchase Plan – share allotment

• Immuron's share purchase plan (SPP) offer closes

• Total amount raised under SPP offer: $442,050

• Termination of SPP underwriting

18 June 2012, Melbourne, Australia: Australian biopharmaceutical company Immuron Limited (ASX: IMC) announced its Share Purchase Plan ( SPP ) has now closed and a total amount of $442,050 has been raised under the SPP offer.

Immuron has also been advised that Patersons Securities Limited has exercised the right under the underwriting agreement to terminate the underwriting of the SPP offer due to market conditions.

The total amount raised through the recent private placements announced on 23 April 2012 and the SPP offer is, accordingly, $1,442,050.

Immuron's CEO, Joe Baini said: "The funds raised from the Share Purchase Plan, together with the earlier $1million private placement, ensure that Immuron is in a good cash position to continue the

® momentum for the commercial roll‐out of Travelan and ongoing discussions with potential

licensees for our promising NASH/fatty liver product. We appreciate the support of our shareholders and Patersons Securities Limited’s management of the offer.

The Company expects the allocation of shares under the SPP offer to be completed in the next few days, at which time the Company's Appendix 3B will be lodged in respect of the allotment.

Contact

Joe Baini – Executive Director +61 3 8637 1107

Rudi Michelson Monsoon Communications +61 3 9620 3333 +61 411 402 737

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy‐derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre‐clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver (NASH), and the prevention of influenza. Immuron has one product in the market, Travelan, for preventing travellers’ diarrhoea. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel), the University of Melbourne and Monash University (Australia).